These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35015265)

  • 1. Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status".
    Pappagallo M; Inturrisi CE; Manfredi PL
    CNS Drugs; 2022 Feb; 36(2):203-204. PubMed ID: 35015265
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Authors' Reply to Pappagallo et al.: Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status".
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2022 Feb; 36(2):205-206. PubMed ID: 35015266
    [No Abstract]   [Full Text] [Related]  

  • 4. Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets.
    Małgorzata P; Paweł K; Iwona ML; Brzostek T; Andrzej P
    Expert Opin Ther Targets; 2020 Dec; 24(12):1187-1209. PubMed ID: 33138678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Glutamatergic conception of mood disorders].
    Permoda-Osip A; Rybakowski J
    Psychiatr Pol; 2011; 45(6):875-88. PubMed ID: 22335130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance spectroscopy studies of the glutamatergic system in mood disorders: a pathway to diagnosis, novel therapeutics, and personalized medicine?
    Salvadore G; Zarate CA
    Biol Psychiatry; 2010 Nov; 68(9):780-2. PubMed ID: 20946973
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
    Machado-Vieira R; Manji HK; Zarate CA
    Neuroscientist; 2009 Oct; 15(5):525-39. PubMed ID: 19471044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamatergic modulators: the future of treating mood disorders?
    Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
    Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.
    Krystal JH; Sanacora G; Blumberg H; Anand A; Charney DS; Marek G; Epperson CN; Goddard A; Mason GF
    Mol Psychiatry; 2002; 7 Suppl 1():S71-80. PubMed ID: 11986998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.
    Machado-Vieira R; Salvadore G; Ibrahim LA; Diaz-Granados N; Zarate CA
    Curr Pharm Des; 2009; 15(14):1595-611. PubMed ID: 19442176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.
    Sanacora G; Zarate CA; Krystal JH; Manji HK
    Nat Rev Drug Discov; 2008 May; 7(5):426-37. PubMed ID: 18425072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of copper and magnesium in the pathogenesis and treatment of affective disorders].
    Siwek M; Wróbel A; Dudek D; Nowak G; Zieba A
    Psychiatr Pol; 2005; 39(5):911-20. PubMed ID: 16358591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabotropic glutamate receptors in the control of mood disorders.
    Witkin JM; Marek GJ; Johnson BG; Schoepp DD
    CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):87-100. PubMed ID: 17430147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.
    Hashimoto K; Malchow B; Falkai P; Schmitt A
    Eur Arch Psychiatry Clin Neurosci; 2013 Aug; 263(5):367-77. PubMed ID: 23455590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders.
    Subramaniapillai M; Carmona NE; Rong C; McIntyre RS
    Dialogues Clin Neurosci; 2017 Mar; 19(1):27-36. PubMed ID: 28566945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GABA and glutamate systems as therapeutic targets in depression and mood disorders.
    Kendell SF; Krystal JH; Sanacora G
    Expert Opin Ther Targets; 2005 Feb; 9(1):153-68. PubMed ID: 15757488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders.
    Ghasemi M; Phillips C; Fahimi A; McNerney MW; Salehi A
    Neurosci Biobehav Rev; 2017 Sep; 80():555-572. PubMed ID: 28711661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.
    Wilkinson ST; Sanacora G
    Drug Discov Today; 2019 Feb; 24(2):606-615. PubMed ID: 30447328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.
    Sanacora G; Treccani G; Popoli M
    Neuropharmacology; 2012 Jan; 62(1):63-77. PubMed ID: 21827775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders.
    Zarate CA; Quiroz J; Payne J; Manji HK
    Psychopharmacol Bull; 2002; 36(4):35-83. PubMed ID: 12858143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.